Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Reversal of cerebrovascular endothelial dysfunction in diabetes: the effect of allopurinol upon cerebrovascular nitric oxide bioavailability
ISRCTN ISRCTN68849312
ClinicalTrials.gov identifier
Public title Reversal of cerebrovascular endothelial dysfunction in diabetes: the effect of allopurinol upon cerebrovascular nitric oxide bioavailability
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Treatment with a xanthine oxidase inhibitor will improve cerebrovascular reactivity in patients with diabetes.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Diabetes
Participants - inclusion criteria 1. Type II diabetes less than 5 years duration, treated with diet, metformin thiazolidinediones or a combination
2. Aged greater than 40 years
3. Normal full Bruce protocol exercise treadmill testing (ETT)
4. Favourable temporal bony window
5. HbA1c less than 9%
6. Cholesterol less than 7.5 mmol/l
Participants - exclusion criteria 1. Greater than 70% Internal carotid artery stenosis
2. Known coronary artery disease
3. Other significant comorbidity
4. Contraindication to allopurinol
5. Concurrent therapy with azathioprine or 6-mercaptopurine
6. Insulin or sulphonylurea treatment
7. Serum creatinine greater than 250 µmol/l
Anticipated start date 01/11/2005
Anticipated end date 01/11/2006
Status of trial Completed
Patient information material
Target number of participants 24
Interventions Two weeks allopurinol versus lactose capsule.
Primary outcome measure(s) The change in internal carotid artery flow following L-NMMA infusion.
Secondary outcome measure(s) 1. Change in serum urate level
2. Change in middle cerebral artery flow velocity
Sources of funding Chief Scientist Office of the Scottish Executive Health Department (UK)
Trial website
Publications 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/18945924
Contact name Dr  Matthew  Walters
  Address Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
  City/town Glasgow
  Zip/Postcode G11 6NT
  Country United Kingdom
  Tel +44 (0)141 211 2821
  Fax +44 (0)141 211 1863
  Email gcl203@clinmed.gla.ac.uk
Sponsor Greater Glasgow NHS Board/Glasgow University (UK)
  Address c/o Judith Godden
Administration Building
Western Infirmary
Dumbarton Road
  City/town Glasgow
  Zip/Postcode G11 6NT
  Country United Kingdom
  Tel +44 (0)141 211 2000
  Email judith.godden@Northglasgow.NHS.Scot.UK
Date applied 09/09/2005
Last edited 05/01/2009
Date ISRCTN assigned 22/11/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central